![The Weekly Break Out Ep. 22: How the US hit Iran, and spooky space moves [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/250622_b2_takeoff_USAF-scaled-e1750776866152.jpg?#)
With competitive pivotal data, Nuvalent eyes FDA rolling submission in crowded lung cancer niche
While three Big Pharma companies have yet to successfully crack the ROS1 lung cancer market, young biotech Nuvalent believes competitive pivotal data from its investigational drug are paving the way to a quick FDA filing and, eventually, a chance at a major opportunity.
While three Big Pharma companies have yet to successfully crack the ROS1 lung cancer market, young biotech Nuvalent believes competitive pivotal data from its investigational drug are paving the way to a quick FDA filing and, eventually, a chance at a major opportunity.
